In order to generate Ad vectors appropriate for localized therapeutic applications in ovarian cancer, we generated a suite of genetically modified vectors that combine mutations within the Ad5 fiber protein that ablate interactions with the native Ad5 receptor, hCAR, with peptide insertions which re-target the recombinant viral vectors to receptors widely recognized as being upregulated in tumors, namely, EGFR and FGFR1. The gene discussed is CXADR; the disease is ovarian cancer.